Company: NYXH
Filing Date: 2025-03-20
Form Type: F-3
Source: 0001104659-25-026217
Chunk: 69

Company: Nyxoah SA
Filing Date: 2025-03-20
Form: F-3
Chunk 69
---
 are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.

<div align='center'>S-9</div>

TABLE OF CONTENTS

### USE OF PROCEEDS
We may issue and sell our ordinary shares having aggregate sale proceeds of up to $50.0 million from time to time. Because there is no minimum offering amount required to be sold in connection with this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We intend to use any net proceeds from the sale of securities under this prospectus supplement to (i) to advance the commercialization of the Genio system in our initial target markets outside the United States and for pre-commercialization and commercialization activities in the United States; (ii) to continue gathering clinical data and to support physician initiated clinical research projects related to OSA patient treatments; (iii) to further finance research and development activities related to the next generation of the Genio system, re-designing our products for manufacturability and cost reduction initiatives, and to continue to build a pipeline of new technologies and explore potential collaboration opportunities in the field of monitoring and diagnostics for OSA; and (iv) for other general corporate purposes, including, but not limited to, working capital, capital expenditures, investments, acquisitions, should we choose to pursue any, and collaborations. The amounts and timing of our actual expenditures will depend on numerous factors, including the progress of our clinical trials and other development efforts and other factors described under “Risk Factors” in this prospectus supplement and the documents incorporated by reference herein, as well as the amount of cash used in our operations. As a result, our management will have broad discretion to allocate the net proceeds, if any, we receive in connection with securities offered pursuant to this prospectus supplement for any purpose.

<div align='center'>S-10</div>

TABLE OF CONTENTS

CAPITALIZATION The following table presents our total capitalization and cash and cash equivalents as of December 31, 2024, on an actual and on an as adjusted basis after giving effect to the sale of our ordinary shares in the aggregate amount of $50.0 million at an assumed offering price of $10.60 per ordinary share, the last reported sale price of our ordinary shares on The Nasdaq Global Market on March 18, 2025, and after deducting commissions and estimated offering expenses payable by us. Our capitalization is derived from our unaudited condensed consolidated